{"id":"rp103","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Musculoskeletal pain"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, RP103 reduces the amount of PCSK9 in the bloodstream, leading to increased levels of low-density lipoprotein (LDL) receptors on the liver surface, which in turn increases the clearance of LDL cholesterol from the blood.","oneSentence":"RP103 is a monoclonal antibody targeting PCSK9.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:56.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT07477288","phase":"PHASE2","title":"Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2025-03-12","conditions":"Skin Aging","enrollment":44},{"nctId":"NCT00359684","phase":"","title":"Use of Cysteamine in the Treatment of Cystinosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"1979-01-04","conditions":"Cystinosis","enrollment":330},{"nctId":"NCT07319091","phase":"NA","title":"Cystinosis and Mitochondrial Metabolism","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01","conditions":"Cystinosis, Native Kidney","enrollment":25},{"nctId":"NCT02012114","phase":"NA","title":"A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-12","conditions":"Cystinosis","enrollment":65},{"nctId":"NCT05994534","phase":"PHASE1, PHASE2","title":"PK and PD Study of NPI-001 and Cysteamine Bitartrate","status":"RECRUITING","sponsor":"Nacuity Pharmaceuticals, Inc.","startDate":"2023-10-29","conditions":"Cystinosis","enrollment":12},{"nctId":"NCT06910813","phase":"PHASE1, PHASE2","title":"DFT383 in Pediatric Participants With Nephropathic Cystinosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-06-02","conditions":"Nephropathic Cystinosis","enrollment":30},{"nctId":"NCT06644534","phase":"PHASE2","title":"A Study to Assess TTI-0102 vs Placebo in MELAS Patients","status":"RECRUITING","sponsor":"Thiogenesis Therapeutics, Inc.","startDate":"2025-05-12","conditions":"MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)","enrollment":12},{"nctId":"NCT06990984","phase":"PHASE2","title":"A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)","status":"NOT_YET_RECRUITING","sponsor":"Thiogenesis Therapeutics, Inc.","startDate":"2025-10","conditions":"Leigh Syndrome","enrollment":18},{"nctId":"NCT03919981","phase":"","title":"CYSTEA-BONE Clinical Study","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-04-05","conditions":"Nephropathic Cystinosis","enrollment":50},{"nctId":"NCT01733316","phase":"PHASE3","title":"Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-31","conditions":"Cystinosis","enrollment":41},{"nctId":"NCT02473445","phase":"PHASE2","title":"A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2015-05-19","conditions":"Mitochondrial Diseases","enrollment":22},{"nctId":"NCT01744782","phase":"PHASE3","title":"Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-12-20","conditions":"Cystinosis","enrollment":17},{"nctId":"NCT01197378","phase":"PHASE3","title":"Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-08-27","conditions":"Cystinosis","enrollment":60},{"nctId":"NCT02023866","phase":"PHASE2","title":"Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-05","conditions":"Inherited Mitochondrial Disease, Including Leigh Syndrome","enrollment":36},{"nctId":"NCT00872729","phase":"PHASE1, PHASE2","title":"Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-05","conditions":"Cystinosis","enrollment":9},{"nctId":"NCT01000961","phase":"PHASE3","title":"Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06","conditions":"Cystinosis","enrollment":43},{"nctId":"NCT05212662","phase":"PHASE2","title":"Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19","status":"WITHDRAWN","sponsor":"Thiogenesis Therapeutics, Inc.","startDate":"2024-09-27","conditions":"COVID-19, COVID-19 Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06278948","phase":"NA","title":"Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma","status":"UNKNOWN","sponsor":"Cosmetique Active International","startDate":"2023-10-06","conditions":"Melasma","enrollment":140},{"nctId":"NCT04125927","phase":"PHASE3","title":"Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2020-09-01","conditions":"Cystinosis","enrollment":5},{"nctId":"NCT05969587","phase":"PHASE3","title":"Cysteamine Compared to Hydroquinone in Melasma","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2019-11-28","conditions":"Melasma","enrollment":28},{"nctId":"NCT05656833","phase":"NA","title":"Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma","status":"UNKNOWN","sponsor":"UnionDerm","startDate":"2022-10-28","conditions":"Melasma","enrollment":20},{"nctId":"NCT05206318","phase":"NA","title":"Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-12-10","conditions":"Hyperpigmentation; Postinflammatory","enrollment":40},{"nctId":"NCT04246060","phase":"","title":"Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Chiesi SA/NV","startDate":"2020-07-31","conditions":"Nephropathic Cystinosis","enrollment":31},{"nctId":"NCT04262895","phase":"PHASE1, PHASE2","title":"TTI-0102 for Veterans With TBI","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2021-10-01","conditions":"Mild to Moderate TBI, Posttraumatic Stress Disorder","enrollment":""},{"nctId":"NCT01529268","phase":"PHASE2, PHASE3","title":"Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-06","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":169},{"nctId":"NCT03883984","phase":"PHASE1","title":"Cysteamine for Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-06-18","conditions":"Asthma","enrollment":60},{"nctId":"NCT03000348","phase":"PHASE2","title":"A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations","status":"COMPLETED","sponsor":"NovaBiotics Ltd.","startDate":"2016-12","conditions":"Cystic Fibrosis","enrollment":91},{"nctId":"NCT00074516","phase":"","title":"Kidney Transplantation in Patients With Cystinosis","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-12-10","conditions":"Cystinosis","enrollment":11},{"nctId":"NCT00715559","phase":"NA","title":"Cysteamine Therapy for Major Depressive Disorder","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2008-07","conditions":"Major Depressive Disorder","enrollment":3},{"nctId":"NCT00028262","phase":"PHASE4","title":"Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2001-02","conditions":"Infantile Neronal Ceroid Lipofuscinosis","enrollment":10},{"nctId":"NCT02766855","phase":"NA","title":"Efficacy of Topical Cysteamine in Nephropathic Cyctinosis","status":"COMPLETED","sponsor":"The Eye Center and The Eye Foundation for Research in Ophthalmology","startDate":"2004-01","conditions":"Nephropathic Cyctinosis, Corneal Cystine Crystals","enrollment":26},{"nctId":"NCT02212431","phase":"PHASE1, PHASE2","title":"First Study of Oral Cysteamine in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2014-08","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT00010426","phase":"NA","title":"Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1999-12","conditions":"Cystinosis","enrollment":30},{"nctId":"NCT01139125","phase":"NA","title":"An Open Trial of Cysteamine Treatment in Schizophrenia","status":"TERMINATED","sponsor":"Augusta University","startDate":"2009-09","conditions":"Schizophrenia, Schizoaffective","enrollment":3},{"nctId":"NCT00001213","phase":"PHASE2","title":"Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1986-04","conditions":"Cystinosis","enrollment":328},{"nctId":"NCT02101957","phase":"PHASE2, PHASE3","title":"Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2010-10","conditions":"Huntington's Disease","enrollment":96},{"nctId":"NCT00799578","phase":"PHASE1, PHASE2","title":"A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Joel Lavine","startDate":"2008-10","conditions":"Fatty Liver","enrollment":13},{"nctId":"NCT01432561","phase":"NA","title":"Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-09","conditions":"Cystinosis, Nephropathic Cystinosis","enrollment":8},{"nctId":"NCT00001736","phase":"PHASE1","title":"New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1998-05","conditions":"Cystinosis","enrollment":51},{"nctId":"NCT00002110","phase":"PHASE2","title":"A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease","status":"COMPLETED","sponsor":"Mylan Laboratories","startDate":"","conditions":"HIV Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cysteamine Delayed-release Capsules","cysteamine bitartrate delayed-release capsules","PROCYSBI®"],"phase":"phase_3","status":"active","brandName":"RP103","genericName":"RP103","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RP103 is a monoclonal antibody targeting PCSK9. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}